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Abstract
Background: Injury and intestinal inflammation trigger wound healing responses that can restore mucosal architecture but
if chronic, can promote intestinal fibrosis. Intestinal fibrosis is a major complication of Crohn’s disease. The cellular and
molecular basis of mucosal healing and intestinal fibrosis are not well defined and better understanding requires well
characterized mouse models.
Methods: FVB-N wild type mice and C57BL6 procollagen a1(I)-GFP reporter mice were given one (DSS1) or two (DSS2)
cycles of 3% DSS (5 days/cycle) followed by 7 days recovery. Histological scoring of inflammation and fibrosis were
performed at DSS1, DSS1+3, DSS1+7, DSS2, DSS2+3, and DSS2+7. Procollagen a1(I)-GFP activation was assessed in DSS and
also TNBS models by whole colon GFP imaging and fluorescence microscopy. Colocalization of GFP with a-smooth muscle
actin (a-SMA) or vimentin was examined. GFP mRNA levels were tested for correlation with endogenous collagen a1(I)
mRNA.
Results: Males were more susceptible to DSS-induced disease and mortality than females. In FVB-N mice one DSS cycle
induced transient mucosal inflammation and fibrosis that resolved by 7 days of recovery. Two DSS cycles induced
transmural inflammation and fibrosis in a subset of FVB-N mice but overall, did not yield more consistent, severe or
sustained fibrosis. In C57BL6 mice, procollagen a1(I)-GFP reporter was activated at the end of DSS1 and through DSS+7 with
more dramatic and transmural activation at DSS2 through DSS2+7, and in TNBS treated mice. In DSS and TNBS models GFP
reporter expression localized to vimentin+ cells and much fewer a-SMA+ cells. GFP mRNA strongly correlated with collagen
a1(I) mRNA.
Conclusions: One DSS cycle in FVB-N mice provides a model to study mucosal injury and subsequent mucosal healing. The
procollagen a1(I)-GFP transgenic provides a useful model to study activation of a gene encoding a major extracellular matrix
protein during acute or chronic experimental intestinal inflammation and fibrosis.
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Introduction
Injury of the intestinal epithelium and acute or chronic
inflammation trigger wound healing responses involving activation
of mesenchymal cells and increased extracellular matrix (ECM)
synthesis, remodeling or deposition [1–3]. Ideally, wound-healing
responses after acute injury or inflammation will lead to mucosal
healing and restoration of normal tissue architecture. However,
chronic or recurring intestinal injury and inflammation can
promote excessive transmural wound-healing responses that lead
to fibrosis. Fibrosis is characterized by excessive ECM deposition,
with procollagen a1(I) representing a prominent ECM compo-
nent, and is often accompanied by distortion of normal tissue
architecture and dysfunction.
Intestinal fibrosis can occur in response to chronic inflammatory
bowel diseases (IBD) including ulcerative colitis (UC) or Crohn’s
Disease (CD) but is most common and problematic in CD [1,3]. In
CD, chronic inflammation is typically transmural, extending
through the mucosal layer to underlying submucosa, muscularis
propria and serosa where mesenchymal cells, which are the major
sources of ECM, reside [1,4]. Fibrostenotic disease, typified by
excessive ECM deposition, thickening of the bowel wall, and
narrowing or stenosis of the intestinal lumen affects approximately
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one third of patients with CD [5]. Despite major progress in
development of anti-inflammatory therapies in CD, progress on
development and clinical testing of anti-fibrotic agents has been
slower. The major treatment for fibrosis in CD is surgical
intervention yet disease and fibrosis recur in many CD patients
necessitating additional surgeries [3,5]. The lack of effective
medical therapies for intestinal fibrosis in part reflects a limited
understanding of the pathophysiology and molecular and cellular
mediators of wound healing and fibrosis in the intestine. Animal
models have made major contributions to our understanding of
the immunological and genetic mechanisms associated with IBD
and have contributed to the development and testing of anti-
inflammatory therapies. The goal of the current study was to
characterize animal models that may be useful for comparisons of
mesenchymal responses associated with mucosal healing after
acute injury and inflammation with mesenchymal responses to
chronic transmural injury that lead to fibrosis. Such models are
desirable as systems to aid better understanding of mechanisms
that underlie normal mucosal healing versus fibrosis and to test
interventions that may prevent or limit fibrosis.
DSS-induced injury and inflammation of the colon has several
attractive features including the technical ease of the model since
DSS is given in drinking water, the lack of requirement for
anesthesia during treatment and existing information that DSS
induces acute mucosal injury and inflammation in mice on
multiple genetic backgrounds [6–9]. We previously reported that
mice on a mixed C57BL6/SJL background show mucosal repair
and disease recovery during 10 days after a single cycle of DSS
[10]. Okayasu et al. reported that oral administration of multiple
cycles of 5% DSS in drinking water of BALB/c mice was able to
induce chronic intestinal inflammation [9]. The current study
examined the impact of one or two cycles of DSS followed by
recovery periods in two commonly used strains of mice, FVB-N
and C57BL6 mice. Our aim was to examine if either or both
strains exhibit mesenchymal cell activation associated with
mucosal healing after one cycle of DSS treatment, or develop
transmural or more severe or sustained fibrosis after a second DSS
cycle or a subsequent recovery period. FVB-N mice were tested
because transgenic or gene deletion models are commonly derived
on this genetic background. Our findings suggest that this genetic
strain of mice exhibits increases in ECM deposition early during
recovery from a single DSS cycle followed by mucosal repair
responses that normalize mucosal architecture. In FVB-N mice,
two DSS cycles did not result in more consistent, sustained or
severe transmural fibrosis although transmural disease was
observed in a subset of animals. Thus DSS colitis in this genetic
background provides opportunities to study mesenchymal re-
sponses during acute mucosal injury and mucosal healing.
Fibrogenic responses to DSS have been previously reported in
mice on the C57BL6 background [11,12]. Our studies examined
responses to one or two DSS cycles in C57BL6 mice expressing a
procollagen a1(I) promoter-GFP reporter transgene to test if this
model may be useful to assess intestinal mesenchymal responses to
acute or chronic intestinal inflammation. We demonstrate that the
reporter is activated during acute or chronic DSS-induced
inflammation and provides a useful tool to visualize, quantify
and define cell types that exhibit activation of gene encoding, a
major component of ECM during fibrosis. Activation of the
procollagen a1(I)-GFP reporter was also confirmed in the TNBS
model of chronic T-cell mediated colitis. In addition, our studies
revealed that compared with females, males on both the FVB-N
and C57BL6 backgrounds showed more limited ability to resolve
disease and had increased mortality after one or two DSS cycles.
This information is important for appropriate design and
interpretation of future studies of DSS colitis and associated




All studies were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of North Carolina at
Chapel Hill (Approved protocol number: 10–197).
Animal Models
Wild Type (WT) FVB-N mice were obtained from a colony
maintained in our specific pathogen-free (SPF) facility. Procollagen
a1(I) promoter-green fluorescent protein (GFP) transgenic mice
(procollagen a1(I)-GFP reporter mice) on a mixed C3H/C57BL6
background were provided by Dr. David Brenner (University of
California, San Diego) and were back-crossed with C57BL6 mice
for more than 10 generations to generate mice on the inbred
C57BL6 background. These mice contain the basal promoter of
the murine procollagen a1(I) gene (23122 to +111 relative to
transcription start site +1) and two upstream DNase sensitive sites
that are important for maximal expression [13].
a-SMA (smooth muscle actin promoter)- Discomsoma sp. red
fluorescence protein (RFP) transgenic mice on CD1 background
were provided by Dr. Scott Magness and were generated as
previously described [14]. a-SMA-RFP mice were back-crossed
with C57BL6 mice for more than 5 generations to generate mice
on C57BL6 background. Both procollagen a1(I)-GFP reporter
mice and a-SMA-RFP mice were maintained as heterozygotes and
were cross-bred to generate procollagen a1(I)-GFP/a-SMA-RFP
dual reporter mice. All genotyping of procollagen a1(I)-GFP, a-
SMA-RFP or a-SMA-RFP/procollagen a1(I)-GFP mice was
conducted by observing fluorescence in a small tail-snip.
Dextran Sodium Sulfate (DSS) Treatment
DSS of molecular weight 30,000–40,000 was purchased from
TDB Consultancy (Uppsala, Sweden). DSS was dissolved in dH2O
to a concentration of 3% wt/vol and changed daily to prevent
bacterial growth. Adult FVB-N mice (n$5 per time point) and
C57BL6 procollagen a1(I)-GFP reporter mice (n = 2 per time
point) were given one or two cycles of 3% DSS (one cycle = 5 days
of 3% DSS) with seven days of recovery between cycles. Animals
were studied at the end of one or two cycles of DSS treatment
(DSS1 or DSS2), and at 3 or 7 days after one (DSS1+3, DSS1+7)
or two (DSS2+3, DSS2+7) cycles of DSS. These time points were
chosen to assess if acute mucosal injury by one cycle of DSS led to
mucosal healing during 7 days of recovery from a single DSS cycle
and if two cycles of DSS led to increased severity of fibrosis or
transmural fibrosis. Age and sex-matched control animals on each
background were given water instead of DSS and were studied in
parallel with treated animals. Animals were weighed daily and
fecal occult blood test was performed every two days to provide
overt measures of disease. Animals were euthanized if they lost
more than 15% body weight or if they became lethargic, immobile
or failed to eat or drink. Data on survival reflects percentage of
animals that did not require euthanasia prior to the study end
point. Histological analyses were performed only on animals that
survived to the assigned study endpoint. Follow-up pilot studies
were performed on dual procollagen a1(I)-GFP/a-SMA-RFP
reporter mice (n = 2) given 1 or 2 DSS cycles to test whether the a-
SMA-RFP reporter might provide advantages over antibody based
methods in defining whether cells exhibiting procollagen a1(I)-
GFP also express a-SMA.
Inflammation Induced Fibrosis in Mice
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Sample Collection
Animals were killed by intraperitoneal injection of an
overdose (150 mg/kg body weight) of sodium pentobarbital
(Nembutal, Ovation Pharmaceuticals Inc. Deerfield, US) and
the entire colon was dissected and flushed with 1X phosphate
buffered saline (PBS)(pH = 7.4). In FVB-N mice, the distal half
of the colon was dissected for analyses since preliminary studies
indicated that this region of colon is most affected. Since it is
known that DSS-induced injury can be focal, the distal half of
the colon was split into three segments for histology as follows:
D1(proximal 1/3 of distal colon), D2 (mid 1/3 of distal colon)
and D3(distal 1/3 of distal colon). Segments D1 and D2 were
fixed in 4% paraformaldehyde (PFA) and Bouin’s fixative
respectively and paraffin embedded. Segment D3 was oriented
in O.C.T. (Tissue-Tek) and frozen on dry ice and isopentane.
Different fixation conditions were used to provide samples
compatible for future immunostaining studies that may require
different fixatives. Sections from D1 and D3 were routinely used
for histological scoring of inflammation and fibrosis on these
two independent segments. D2 was used only if histology was
suboptimal in D1 or D3 of a given animal. For procollagen
a1(I)-GFP reporter mice and procollagen a1(I)-GFP/a-SMA-
RFP mice, whole colon was dissected and imaged for GFP then
fixed in 4% PFA, cryoprotected in sucrose and embedded in
O.C.T. for histology or immunofluorescence. A small segment
at the distal end of the proximal half of the colon was frozen
for RNA extraction.
Histological Assessment of Inflammation and Fibrosis in
FVB-N Mice
The distal colon was evaluated as this is the most severely
affected colonic segment in DSS-induced colitis [6,9]. Severity of
colitis was scored on H&E stained colon sections by a blinded
observer [10]. Sections from segments D1 and D3 were evaluated
for each animal and an average of scores in the two segments was
used as the score for each individual animal. Segment D2 was
scored only on a subset of animals if tissue quality of other
segments was poor. Briefly, inflammation severity, inflammation
extent and crypt loss were each given a score ranging from 0–4
and each score was multiplied by the extent of the section involved
(0 = 0; #25% = 1, #50% = 2; #75% = 3 and #100% = 4). Total
colitis score is the sum of the scores for inflammation severity,
inflammation extent and crypt loss and was calculated as the
average of total colitis scores from D1 and D3 in a given animal.
Fibrosis was scored by a blinded observer on adjacent sections
from segments D1 and D3 stained with Masson’s Trichrome
(stains collagen and proteoglycans) or Sirius red (stains fibrillar
collagen). The scoring criteria used for fibrosis are shown in
Table 1 and fibrosis score for each animal is the average of scores
for segments D1 and D3. Histological evaluation and scoring was
performed using a Nikon Microphot-FXA microscope equipped
with an Optronics DEI 750-3-chip CCD camera for digital
imaging.
Enhanced GFP (EGFP) Imaging in DSS Treated
Procollagen (a1)I-GFP Mice
Whole colon was dissected and immediately imaged using a
charge-coupled device camera in a light-tight imaging box with a
dual-filtered light source and emission filters specific for EGFP
(LT-99D2 Illumatools; Lightools Research, Encinitas, CA).
Identical exposure times were used to capture images from each
animal.
Real Time PCR Analyses
Total RNA was extracted from segment of colon from each
DSS treated procollagen a1(I)-reporter animal using the RNeasy
Mini Kit (Qiagen) according to manufacturer’s instructions.
Reverse-transcription was performed using AMV-RT (Promega).
Quantitative real time PCR analyses were completed on the
Rotorgene 2000 (Qiagen) using Invitrogen Platinum qPCR
Supermix-UDG and the following Taqman primer-probe sets
(Applied Biosystems): mouse collagen a1(I) Mm00801666_g1,
customized mouse EGFP Taqman primers (Forward: 59-
AGTCCGCCCTGAGCAAAGA-39, Reverse: 59-TCCAGCAG-
GACCATGTGATC-39) and probe (59 6-FAM-CCCAACGA-
GAAGCG-MGB-39). 18 S Mm03928990_g1was used as an
invariant control. Non-reverse transcribed samples were used as
negative controls. Collagen a1(I) mRNA in each sample was
normalized to 18 S mRNA.
Immunofluorescence Staining
To establish mesenchymal cell types that exhibited procollagen
a1(I)-reporter expression, cellular sites of GFP expression were
compared with sites of vimentin or a-smooth muscle actin (a-
SMA) using immunofluorescence. Before the primary antibody
incubation, frozen sections were pretreated with 0.05 M Tris
Triton (TT) epitope retrieval solution at room temperature (RT)
for 30 minutes and blocked in 5% normal goat serum (NGS)
diluted in TT buffer for 1 hr and subsequently incubated with
primary antibodies (a-SMA, Cat#04–1094, 1:200, Millipore,
Billerica, MA; Vimentin, Cat# NBP-140730, 1:500, Novus
Biologicals, Littleton, CO) that were diluted in 5% NGS/TT
buffer overnight at 4uC. Detection of primary antibodies was
performed with secondary antibodies (Goat anti mouse Cy3,
Cat#115–165–166, 1:500; Goat anti Rabbit Cy3, Cat#111–165–
144, 1:500, Jackson Immuno) for 1 hr at RT. Nucleic acid staining
was carried out by labeling with bisbenzamide for 10 minutes.
Following three washes with 0.05 M Tris buffer, coverslips were
mounted in gel-mount (Electron Microscopy Sciences, Hatfield,
PA). Photomicrographs were collected using a Nikon Eclipse E800
(Melville, NY) fluorescence microscope. Procollagen a1(I)-GFP
and a-SMA-RFP activation were detected by fluorescence
microscopy.
TNBS Induced Colitis
Procollagen a1(I)-GFP reporter mice were treated with TNBS
ethanol to induce colitis according to the method reported by
Wirtz [15]. TNBS treatment is known to activate T cells even
during periods of early acute inflammation [15,16]. We therefore
used this model to test if the procollagen a1(I)-GFP reporter is
activated in response to T cell mediated colitis. Briefly, on day 1,
mice were presensitized with 150 ml TNBS presensitization
solution (4 volumes of acetone/olive oil with 1 volume of 5%
TNBS to obtain 1% (w/v) TNBS) administered on shaved skin on
the back of the animal. Control animals were given presensitiza-
tion solution without TNBS. Eight days later, the mice were
anesthetized under isofluorane and given TNBS/ethanol (2.5 mg/
mouse TNBS +50% ethanol, 0.1 ml) by enema. Control animals
were given enema with only 50% ethanol or water. Mice were
euthanized five days later. Whole colon was dissected, GFP was
visualized and then colon was fixed in 4% PFA, cryoprotected in
sucrose and embedded in O.C.T. for histological analyses.
Statistical Analysis
Values are expressed as mean 6 standard error (SE) or
presented as values for individual animals. Mean histological
Inflammation Induced Fibrosis in Mice
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scores were analyzed by one-way ANOVA followed by pair wise
comparisons using Tukey’s post-hoc test. Statistical analyses of
histological inflammation and fibrosis include only females since
few males survived to study endpoint. Regression analyses were
performed to test for correlations between histological measures of
inflammation and fibrosis or procollagen a1(I)-GFP activation.
Regression analysis was also performed to test for correlations
between EGFP mRNA and collagen a1(I) mRNA in colon of
C57BL6 procollagen a1(I)-GFP reporter mice. A p value ,0.05
was considered statistically significant.
Results
Clinical Indices of Disease in FVB-N Mice and Collagen-
GFP B6 Mice
As a group, FVB-N mice tolerated 1 or 2 cycles of 3% DSS
followed by recovery with an overall survival rate of 86%.
However, over the course of treatment, survival of female mice
was greater (98%) than survival of males (73%). Of the male mice
that did not survive until the intended study time, 73% required
euthanasia during the first recovery period, and the remaining
27% required euthanasia during the second cycle of DSS or
subsequent recovery period. None of the male mice originally
designated for study at DSS2+7 survived until that study time.
Therefore, data obtained at this time point reflects only female
mice.
Consistent with the higher survival observed in female FVB-N
mice, DSS treatments were associated with minimal weight loss in
female FVB-N mice and more dramatic weight loss in male FVB-
N mice. As shown in Figure 1A, males given DSS showed a
decline in body weight during the first 4 days after one cycle of
DSS treatment. Those male mice that survived then began to
regain weight but male mice given a second cycle of DSS showed a
progressive decline in body weight throughout the second DSS
cycle and recovery. Hemoccult testing was used as a measure of
bleeding associated with active injury and inflammation induced
by DSS. Virtually 100% of females became hemoccult positive by
the end of DSS treatment, but then this rapidly declined back to
baseline after 7 days of recovery indicative of mucosal healing
(Figure 1B). A similar pattern was observed after 2 DSS cycles
(Figure 1B). Consistent with greater disease susceptibility in males,
a larger proportion of the males that did not require euthanasia
remained hemoccult positive during the initial 7 days of recovery
after one DSS cycle (Figure 1B).
FVB-N Mice Show Mucosal Healing after One DSS Cycle
but not Sustained Fibrogenic Responses after Two DSS
Cycles
Figure 2A shows representative H&E stained sections at
different times after one or two DSS cycles and illustrates that
inflammation was largely confined to the mucosa at the end of
one DSS cycle, became most severe and extended into
submucosa at DSS1+3 and then partially resolved after 7 days
of recovery. Total colitis scores (Figure 2B) provide quantitative
evidence that inflammation and mucosal damage were maxi-
mum at DSS1+3. By DSS1+7, mean colitis scores did not differ
significantly from water controls, indicating that mucosal healing
and resolution of inflammation occurred in a majority of
animals by this time point. After two DSS cycles, inflammation
extended to the submucosa by DSS2+3 and in a subset of
animals, extended through the muscularis propria and serosal
layers by DSS2+7 (Figure 2A). Mean colitis scores were
significantly elevated above water controls at DSS2+7 but were
not as high as observed at DSS1+3.
Representative Masson’s Trichrome- and Sirius red-stained
sections are shown in Figure 3, along with adjacent sections
stained with H&E. Increased ECM deposition was apparent in
the lamina propria, especially in regions of severe crypt damage
and inflammation. The most dramatic increases in ECM
deposition occurred in the submucosa, with strong collagenous
bands evident adjacent to the muscularis mucosa during
recovery from one cycle of DSS treatment. After 2 DSS cycles,
a subset of animals showed transmural fibrosis with increased
ECM being evident in submucosa, muscularis propria and
serosa (Figure 3B).
Fibrosis was scored by a blinded observer using the semi-
quantitative scheme outlined in Table 1. Mean fibrosis scores in
each group are shown in Figure 4. Post-hoc analyses revealed
that the mean fibrosis score was significantly elevated above
water controls at DSS1+3, DSS2 and DSS2+3. However, the
mean fibrosis scores at DSS1+7 and DSS2+7 were not
significantly greater than water controls. This suggests that
increased ECM after one or two DSS cycles is transient and
followed by a return towards normal levels within 7 days after
DSS. Regression analysis on colitis scores and fibrosis scores
across all time points indicated a strong and highly significant
correlation (r2 = 0.82, p,0.005).
Table 1. Histological fibrosis scoring method.
Category Score Description
Collagen (fibrosis) 0 No increase
1 Increased in the submucosa
2 Increased in the mucosa
3 Increased in the muscularis mucosa; thickening/disorganization of the muscularis mucosa
4 Increased in the muscularis propria (evident increases in collagen fibrils for Sirius red)
5 Gross disorganization of the muscularis propria; increased Sirius red/GFP or thickening of
the serosa
Percent involvement 1 1–25% of section
2 26–50% of section
3 51–75% of section
4 76–100% of section
doi:10.1371/journal.pone.0042568.t001
Inflammation Induced Fibrosis in Mice
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Procollagen a1(I)-GFP Mice as a Useful Reporter for
Intestinal Fibrosis
We assessed procollagen a1(I)-GFP mice after one or two DSS
cycles and after TNBS treatment to test if this model may provide
a useful reporter for mesenchymal cell activation and fibrosis.
Since these mice are on a C57BL6 background, this allowed us to
test whether the gender specific differences in disease severity
observed in DSS-treated FVB-N mice were also observed in mice
on the widely used C57BL6 genetic background. As shown in
Table 2, female C57BL6 mice lost less weight than males over the
course of two DSS cycles and recovery. In addition, one third of
the males tested required euthanasia while all females survived.
Thus, across two separate genetic backgrounds, males are more
susceptible to DSS colitis than females.
As shown in Figure 5, evaluation of entire colon from water
controls or DSS treated mice revealed that collagen GFP
expression was obviously and dramatically induced in mid and
distal colon by DSS1+7 and at all time points after 2 DSS cycles
(Figure 5A). White light pictures of the same colon tissue
demonstrate enlarged mid and distal colon at DSS1+7 and
subsequent times. H&E staining (Figure 6) demonstrated that in
contrast to FVB-N mice, C57BL6 mice do not show mucosal
Figure 1. DSS treated male FVB-N develop more severe disease that females. (A) Percentage body weight change in male and female FVB-
N mice after one or two cycles of DSS treatment. (B) Percentage of hemoccult positive male and female FVB-N mice treated with DSS. Data are
presented as mean 6 SEM of 6–14 mice per treatment group. DSS1: one cycle of DSS; DSS2: two cycles of DSS; R1: recovery period after one cycle of
DSS; R2: recovery period after two cycles of DSS.
doi:10.1371/journal.pone.0042568.g001
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healing during the 7 days following one DSS cycle. Inflammation
and crypt loss progressively worsened from the end of one cycle of
DSS up to DSS1+7 and a second DSS cycle led to very severe
transmural inflammation which did not resolve by DSS2+7.
Evaluation of GFP on the same sections as stained with H&E
(Figure 6) revealed that the procollagen a1(I)-GFP reporter was
activated at the end of one DSS cycle and through 7 days of
recovery with induction primarily in lamina propria, submucosa
and scattered cells within muscularis propria and serosa. After two
DSS cycles, maximal intense and transmural activation of collagen
GFP was still apparent through DSS2+3 and DSS2+7. To
establish if procollagen a1(I)-GFP activation could provide a
semi-quantitative measure of fibrosis, whole colon GFP intensity
was assessed using ImageJ 1.43u, NIH, USA. A histologic fibrosis
score was obtained from Masson’s Trichrome stained sections of
distal colon using the fibrosis scoring criteria listed in Table 1.
Colitis score was obtained on H&E sections from the same colon
segment (n = 2 for each time point). Whole colon GFP intensity,
fibrosis score from Masson’s Trichrome staining and colitis scores
were elevated from DSS1+3 onwards (Figure 5B). Regression
analysis revealed that whole colon GFP intensity correlated
significantly with a histological fibrosis score based on Masson’s
Trichrome staining (r2 = 0.742, p,0.001) and with histological
colitis score (r2 = 0.669, p = 0.002). The histological fibrosis score
based on Masson’s Trichrome staining also significantly correlated
with colitis score (r2 = 0.738, p,0.0001). Regression analysis
(Figure 5C) showed strong and significant correlation between
GFP mRNA expressed due to activation of the procollagen a1(I)-
GFP transgene and endogenous collagen a1(I) mRNA (r2 = 0.76,
p,0.001), providing evidence that the procollagen a1(I)-GFP
reporter provides a valid measure of injury or inflammation
induced activation of a gene encoding a major component of
fibrotic ECM. Furthermore, the strong correlation between whole
colon GFP and fibrosis scores provides evidence that imaging GFP
on whole colon could be useful and convenient to evaluate or test
impact of genetic or therapeutic interventions on procollagen
a1(I)-GFP expression associated with acute wound healing
responses or fibrosis, especially in high throughput studies.
Figure 2. Two cycles of DSS treatment induce sustained, severe and transmural inflammation in FVB-N mice colon. (A) Representative
photomicrographs of H&E staining on distal colon of FVB-N mice after DSS treatment (10X). (B)Total colitis score in colon of DSS-treated FVB-N mice.
Data are presented as mean 6 SEM. a: p,0.05 versus scores in water control mice.
doi:10.1371/journal.pone.0042568.g002
Inflammation Induced Fibrosis in Mice
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Figure 3. Histological analysis demonstrate induction of submucosal and transmural collagen deposition in DSS treated mice
colon. (A) Hemotoxylin and eosin (H&E), Sirius red staining (SR) and Masson’s Trichrome staining (MR) on FVB-N mice colon at different time points
during DSS treatments (10X). (B) High power photomicrographing of Sirius red staining in sections of colon from FVB-N given 2 DSS cycles to
illustrate muscularis and transmural collagen deposition (black arrows) (20X).
doi:10.1371/journal.pone.0042568.g003
Inflammation Induced Fibrosis in Mice
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One or Two DSS Cycles Induce Procollagen a1(I)-GFP
Reporter Expression in Cells Expressing Antigenic
Markers of Fibroblasts and Myofibroblasts
Multiple fibrogenic mesenchymal cells including fibroblasts
(vimentin+/a-SMA2), myofibroblasts (vimentin+/a-SMA+) and
smooth muscle cells (vimentin2/a-SMA+) have been implicated
in intestinal fibrosis [1]. The localizing of GFP was compared with
either vimentin or a-SMA on the adjacent sections, and
fluorescence signals were compared with H&E stained adjacent
sections to reveal histology. Qualitative evaluation of low power
images (Figure 6) demonstrates that in the 7 days following one or
two DSS cycles, there is a dramatic expansion of both GFP and
vimentin positive cells within mucosa, submucosa and disorga-
nized muscularis propria and serosa. In contrast, a-SMA
antibodies stained primarily muscularis mucosa and muscularis
propria. Colocalization of GFP with vimentin or a-SMA was
further assessed by examination of sections under high power
magnification. As shown in Figure 7, the number of cells showing
colocalization of GFP and vimentin was dramatically increased
after DSS treatment, especially in the mucosa and submucosa.
After 1 or 2 cycles of DSS, the majority of mucosal and
submucosal GFP+ cells are also vimentin+ with scattered GFP+/
vimentin+ cells were also evident in muscularis and present in
serosa. Figure 8 also shows there are relatively few GFP+ cells
which colocalize with a-SMA+ in water controls or after one DSS
cycle. After two DSS cycles, a few double positive GFP+/a-SMA+
cells (myofibroblasts) were found in mucosa, but the GFP+ cells in
submucosa or muscularis layers did not show positive a-SMA-
immunofluorescence. Together the GFP, vimentin and a-SMA
data indicate that fibroblasts are the primary cell type exhibiting
activation of the procollagen a1(I)-GFP reporter gene. However,
one caveat to this conclusion is whether there may be cells
expressing GFP in the submucosa or muscularis that do express a-
SMA and have myofibroblast phenotype, but that these cells are
poorly detected by immunofluorescence with a-SMA antibodies
because the levels of expression are lower than in smooth muscle
cells within muscularis propria. To attempt to address this issue,
we performed preliminary analyses in procollagen a1(I)-GFP/a-
SMA-RFP dual reporter mice given one or two DSS cycles.
As shown in Figure 9, in colon of water controls a-SMA-RFP
reporter expression was abundant in muscularis propria and
evident in muscularis mucosa, but little or no expression was
detected in lamina propria and submucosa. One DSS cycle
induced a-SMA-RFP reporter expression in mucosa and submu-
cosa. In mice given two cycles of DSS, more cells expressing a-
SMA-RFP reporter were detected in mucosa and submucosa.
Evaluation of GFP on the same sections revealed overlap between
many of the RFP positive cells and GFP although still many more
GFP+ than RFP+ cells. Also, after two DSS cycles, regions of
disorganized muscularis propria showed scattered a-SMA-RFP+
cells, which colocalized with procollagen a1(I)-GFP and a very
small number of dual positive cells were detected in grossly normal
muscularis propria. Together, these findings suggest that after
DSS, there is a subpopulation of cells that co-express procollagen
a1(I)-GFP reporter and a-SMA or a-SMA-RFP reporter.
Procollagen a1(I) Reporter is Activated during TNBS
Colitis
TNBS induced colitis is characterized by transmural inflamma-
tion of the colon that shares some histopathological features with
Figure 4. Two cycles of DSS did not induce more severe fibrogenic responses in FVB-N mice. Fibrosis scores in colons of FVB-N mice at
different time points during DSS treatment. Data are presented as mean 6 SEM of 6–10 mice per treatment group. a: p,0.05 versus scores in water
control mice.
doi:10.1371/journal.pone.0042568.g004
Table 2. Body weight loss and survival rate of DSS treated
C57BL6 mice.




DSS1 DSS1+7 DSS2 DSS2+7
Control (M+F, n = 3) 0 0 0 0 100%
Female (n = 4) 2% 5.5% 7.2% 3.5% 100%
Male (n = 3) 2% 21.5% 17.3% * 66%
*did not measure due to high mortality/need for euthanasia.
(Data reflect non-transgenic littermates as well as procollagen a1(I)-GFP mice at
each time).
doi:10.1371/journal.pone.0042568.t002
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Figure 5. Procollagen a1(I)-GFP reporter expression is induced in mice colon after DSS treatment and recovery. (A) Representative
white light and GFP images of whole colon from collagen GFP reporter mice after DSS treatment. (B) Quantitative data for whole colon intensity,
fibrosis score from Masson’s Trichrome (MT) staining and colitis score for each animal (n = 2 per treatment group and time point). (C) Regression
analysis on EGFP mRNA and collagen a1(I) mRNA in colon of C57BL6 procollagen a1(I)-GFP reporter mice(r2 = 0.76, p,0.001).
doi:10.1371/journal.pone.0042568.g005
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human Crohn’s Disease [17]. Even early TNBS colitis is
associated with T-cell-mediated inflammation [15,18]. Visualiza-
tion of entire colon revealed increased procollagen a1(I)-GFP
reporter activation in the most distal portion of the colon in TNBS
treated animals versus ethanol treated or untreated controls. This
corresponds to the region exposed to enema. H&E staining of
Figure 6. Low power images of H&E, GFP, vimentin and a-SMA staining from DSS treated mice colon (4X). This indicates progressively
greater and transmural activation of the procollagen a1(I)-GFP reporter after 2 DSS cycles. Both GFP and vimentin positive cells were expanded within
mucosa, submucosa and muscularis propria and serosa. However, a-SMA antibodies stained primarily muscularis mucosa and muscularis propria.
doi:10.1371/journal.pone.0042568.g006
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colon sections (Figure 10B) verified that one enema with TNBS
given after skin sensitization caused transmural inflammatory
infiltration and thickening of muscularis layer. Procollagen a1(I)-
GFP expression was induced throughout lamina propria, submu-
cosa and scattered cells within the muscularis propria. Similar to
the DSS model, colocalization studies revealed that a majority of
submucosal GFP+ cells are also vimentin+ and that GFP+/
vimentin+ cells are evident in muscularis. A few cells in the mucosa
Figure 7. High power images of colocalization vimentin(red) and procollagen a1(I)-GFP (green) on DSS treated mice colon. Overlay
(yellow cells, high power) demonstrates extensive colocalization of vimentin and GFP.
doi:10.1371/journal.pone.0042568.g007
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expressed both GFP and a-SMA. In contrast, there was essentially
no overlap between procollagen a1(I)-GFP reporter and a-SMA in
submucosa or muscularis when evaluated by immunofluorescence.
Discussion
A major goal of the current study was to assess wound healing
and fibrogenic responses to acute and chronic DSS induced
Figure 8. High power images of colocalization a-SMA (red) and procollagen a1(I)-GFP(green) on DSS treated mice colon. Overlay
demonstrates very limited co-localization in mucosa (white arrows). No colocalization was detected in submucosa and muscularis.
doi:10.1371/journal.pone.0042568.g008
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Figure 9. DSS induced procollagen-GFP+/a-SMA-RFP+ cells in mucosa, submucosa and muscularis layers in dual reporter mouse
colon. Dual reporter gene transgenic mice were treated with one cycle of DSS (DSS1) or two cycles of DSS (DSS2), Fluorescence microscopy images
indicate dramatic increased colocalization of GFP(+) cells with a-SMA-RFP(+) cells in mucosa and transmural fibrosis (white arrows).
doi:10.1371/journal.pone.0042568.g009
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mucosal injury and inflammation based on changes in extent and
site of ECM deposition. We compared responses to DSS in two
inbred mouse strains commonly used to derive genetically
manipulated mice and assessed the utility of a procollagen a1(I)-
GFP reporter mouse as a readout for activation of a gene encoding
a major ECM protein during DSS or TNBS induced disease. Our
results provide important information relevant to use of the DSS
model and a new reporter mouse to test impact of interventions or
genetic manipulations on normal mucosal healing and fibrosis.
Our findings that males on both FVB-N and C57BL6
backgrounds exhibit more weight loss, more persistent hemoccult
positivity and higher mortality/need for euthanasia demonstrate
that males develop more serious disease or disease complications
during the recovery period after DSS, especially after one cycle of
DSS. Practically, such findings suggest that data in males and
females need to be analyzed separately when evaluating impact of
therapeutic/prophylactic interventions or genetic manipulations
on disease severity, wound healing or fibrosis. However, lower
Figure 10. GFP reporter expression is induced in TNBS colitis model. (A) Representative white light and GFP images of whole colon from
procollagen a1(I)-GFP reporter mice after one enema of TNBS versus ethanol or water control. Note increased GFP in distal colon of TNBS (and to a
lesser extent, ethanol) treated mice. (B) Low power images of H&E and procollagen GFP activation obtained from control and TNBS treated mice
colon (10X). (C) High power images demonstrate that GFP reporter expression is induced in submucosa and muscularis propria in colon of TNBS-
treated mice. (D) High power images from immunostaining demonstrate colocalization of vimentin and GFP (white arrows) in submucosa and
muscularis. Limited colocalization of a-SMA+ and GFP+ cells were detected in mucosa but not in submucosa and muscularis.
doi:10.1371/journal.pone.0042568.g010
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amounts of DSS (2 or 2.5% of DSS) than the 3% DSS used here
may improve survival in males and may be a useful strategy for
investigators including males in their study. Our findings of sex-
dependent differences in susceptibility to DSS are consistent with
prior reports that male C3H/HeJ mice developed more severe
DSS-induced colonic lesions [7] and that across a number of
mouse strains, females were more resistant to DSS-induced disease
[8]. Our findings are also relevant to emerging evidence that IBD
susceptible loci including Toll-like receptor 8 reside on the X
chromosome [19,20].
In FVB-N mice, the most severe colitis and fibrosis was
observed after 3 days of recovery following one cycle of DSS. By
7 days of recovery, DSS treated FVB-N mice showed reduced
colitis and fibrosis scores which did not differ significantly from
water controls. This suggests that FVB-N mice exhibit only
transient increases in ECM deposition and mucosal healing
between 3 and 7 days after one DSS cycle. This pattern of disease
provides evidence that evaluation of the recovery period after one
DSS cycle in FVB-N mice could be particularly useful to test
whether particular interventions or genetic manipulations accel-
erate or improve mucosal healing, which is currently considered
an important therapeutic and prognostic indicator in CD [21].
FVB-N mice subjected to one DSS cycle and recovery could also
prove useful to explore differences in molecular or functional
phenotypes of mesenchymal cells at times after DSS associated
peak mucosal damage and ECM deposition versus times
associated with mucosal healing and restoration of normal
mucosal architecture. In FVB-N mice, two DSS cycles and a
7 day recovery period resulted in transmural increases in ECM in
a subset of animals but overall did not consistently lead to more
severe or sustained fibrosis. This suggests that FVB-N mice may
need more DSS cycles to induce severe transmural fibrosis or may
be resistant to development of fibrosis. Alternative mouse models
of chronic intestinal inflammation and fibrosis exist including one
or multiple cycles of intrarectal TNBS treatment [22–26] or
salmonella infection [27]. Each of these models and the DSS
model have strengths and limitations as models of IBD. However,
the technical ease of the DSS model, and the transient fibrogenic
changes and subsequent mucosal healing in FVB-N mice during
recovery from one DSS cycle, provides a potentially useful and
readily accessible model for initial testing of interventions or
therapies that may impact these processes.
Our studies in procollagen a1(I)-GFP reporter mice aimed to
test whether the reporter gene is activated during acute DSS-
induced injury or more chronic inflammation and provide proof of
principle as to whether levels or sites of reporter gene activation in
whole colon or histologically could provide a useful readout of
mesenchymal cell activation. Procollagen a1(I)-GFP mice have
proved useful to investigate the cellular mechanisms of liver
fibrosis [28,29]. Increased expression and deposition of type I
collagen is a major component of fibrosis in CD and intestinal
stricture formation [25,30]. Histology on procollagen a1(I)-GFP
mice demonstrated that in contrast to FVB-N mice, mice on
C57BL6 background did not show mucosal healing through
7 days of recovery after a single DSS cycle and disease
progressively worsened to severe and transmural colitis after 2
DSS cycles. These findings are consistent with prior reports that
C57BL6 mice do not show mucosal healing but develop chronic
colitis after a single DSS cycle [11,12]. Importantly, transmural
colitis was associated with transmural activation of the procollagen
a1(I)-GFP reporter gene, suggesting activation of mesenchymal
cells to increase expression of a major component of fibrotic ECM.
Strong and significant correlations between whole colon GFP
intensity and histologic fibrosis scores, and between GFP mRNA
and endogenous collagen a1(I) mRNA provide important evidence
that procollagen a1(I)-GFP reporter activation provides a rapid
and easy measure of activation of fibrogenic processes and
induction of a major ECM gene, and could be potentially useful
to study responses to interventions aimed at limiting fibrosis. We
recognize that more studies will be required to definitively
establish if procollagen a1(I)-GFP activation faithfully reflects
development of fibrosis or increased expression or deposition of
ECM proteins. We back-crossed the procollagen a1(I)-GFP mice
onto the C57BL6 background to facilitate cross-breeding of this
model with genetically manipulated mice on this same background
in order to test genetic manipulations that may impact activation
of this key fibrogenic gene. Confirmation that the procollagen
a1(I)-GFP reporter is activated in the alternate TNBS and T cell
driven model of colitis further supports the utility of the
procollagen a1(I)-GFP reporter model. Histological findings that
procollagen a1(I)-GFP expressing cells are located mainly in
mucosa and submucosa after one DSS cycle and recovery,
followed by transmural activation in cells throughout the bowel
wall, including muscularis and serosa after two DSS cycles,
demonstrate that the reporter will provide a useful tool to visualize
and study the molecular or functional phenotypes of mucosal,
submucosal and muscularis- or serosa-based mesenchymal cells
that are activated to express this key fibrogenic gene.
Current views implicate myofibroblasts or modified smooth
muscle cells as major mediators of transmural fibrosis in CD
[1,30]. However, it is important to note that one detailed study in
tissues from patients with CD documented increases in vimentin+/
SMA2 fibroblasts as well as vimentin+/SMA+ cells in regions of
fibrosis in CD [4]. Our comparison of the cellular sites of
procollagen a1(I)-GFP expression and a-SMA or vimentin
immunoreactive cells indicates that in response to DSS or TNBS
colitis, vimentin positive cells are by far the most abundant cell
types exhibiting activation of procollagen a1(I)-GFP in mucosa,
submucosa, serosa and, muscularis layers. This suggests that cells
with fibroblast phenotype are the primary cell type activated to
express procollagen a1(I) in the DSS and TNBS models. Similar
conclusions were reached by Suzuki et al [12] who colocalized
type I collagen with vimentin or a-SMA. After two DSS cycles,
however, in both DSS and TNBS models, we did observe a-SMA+
cells with activated procollagen a1(I)-GFP reporter in the lamina
propria but not submucosa or muscularis. This may suggest that
mucosal rather than submucosal fibroblasts are activated to
myofibroblast phenotype in both models because of injury initiated
in epithelium and mucosa. Given that transmural activation of
cells to myofibroblast phenotype is involved in fibrosis associated
with IBD, this should be considered a limitation of the DSS and
acute TNBS models in terms of relevance to CD fibrosis.
However, it is also important to consider the possibility that
immunofluorescence approaches may underestimate the number
of myofibroblasts co-expressing reporter and a-SMA if levels of
SMA are, for example, lower than in smooth muscle cells.
Preliminary studies in a new dual reporter model expressing an a-
SMA-RPF reporter as well as the procollagen a1(I)-GFP reporter
suggest that this may be the case. In this model, dual labeled cells
were observed in both submucosa and disorganized muscularis as
well as mucosa. This emphasizes that characterization of
mesenchymal cell types involved in injury or inflammation-
induced fibrosis may require multiple approaches to definitively
assess cell phenotype. Clearly more will need to be done to
definitively identify the cell types expressing procollagen a1(I)-GFP
reporter and their relevance to wound healing after acute injury or
to transmural fibrosis associated with chronic inflammation.
However, the procollagen a1(I)-GFP reporter provides a poten-
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tially useful and valuable system to apply flow cytometry based
methods to compare, quantify and isolate cells showing activation
of a key fibrogenic gene at different times during wound healing or
fibrosis in DSS or other IBD and intestinal injury models.
Fluorescence activated cell sorting of cells expressing the
procollagen a1(I)-GFP reporter, combined with antibody based
sorting for a-SMA or vimentin may provide a more complete or
sensitive evaluation of the numbers of cells co-expressing GFP
reporter and myofibroblast or fibroblast biomarkers at different
stages of DSS or TNBS induced disease and fibrogenic changes.
Such studies will also provide unique opportunities to define
molecular and functional changes in different populations of
fibrogenic cells during injury, fibrosis or therapeutic interventions.
We should also emphasize that the visualization of GFP by
fluorescence microscopy may complement and have benefits
relative to localization of cell specific antigens on Sirius red or
Masson’s Trichrome stained sections, because GFP is intracellular,
while secretion and deposition of ECM in the extracellular
compartment can make it difficult to definitively establish the
precise cell types that are sources of ECM/collagen. The dual
reporter model offers additional opportunities to compare,
quantify and isolate a-SMA positive and a-SMA negative
procollagen a1(I)-GFP expressing cells in DSS, TNBS or other
intestinal injury and inflammation models. Our current prelimi-
nary studies provide an important first step towards more
extensive characterization of this model and its value and validity
for studies of the cellular and molecular basis of intestinal fibrosis.
In conclusion, the current study characterizes DSS-induced
mucosal injury, and mucosal healing in FVB-N mice and DSS or
TNBS-induced colitis and fibrosis in C57BL6 procollagen a1(I)-
GFP reporter mice as an important step to use of these models to
better understand mechanisms of mucosal healing and fibrosis.
Our study demonstrates activation of the procollagen a1(I)-GFP
reporter during acute mucosal injury or chronic, transmural
inflammation. This provides an essential first step to further use of
this model to better define cellular mediators and molecular
phenotypes of mesenchymal cells, or potentially other cell types,
that are activated during acute mucosal injury, or during chronic
inflammation and progressive fibrosis, and to test interventions
that may impact these processes.
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